Rapid systemic surge of IL-33 after severe human trauma: a prospective observational study.
Alarmins
Biomarkers
Critical Care
Humans
Immunity
Innate
Interleukin-33
Kinetics
Prospective Studies
Wounds and Injuries
Journal
Molecular medicine (Cambridge, Mass.)
ISSN: 1528-3658
Titre abrégé: Mol Med
Pays: England
ID NLM: 9501023
Informations de publication
Date de publication:
26 03 2021
26 03 2021
Historique:
received:
02
04
2020
accepted:
08
03
2021
entrez:
27
3
2021
pubmed:
28
3
2021
medline:
24
11
2021
Statut:
epublish
Résumé
Alarmins are considered proximal mediators of the immune response after tissue injury. Understanding their biology could pave the way for development of new therapeutic targets and biomarkers in human disease, including multiple trauma. In this study we explored high-resolution concentration kinetics of the alarmin interleukin-33 (IL-33) early after human trauma. Plasma samples were serially collected from 136 trauma patients immediately after hospital admission, 2, 4, 6, and 8 h thereafter, and every morning in the ICU. Levels of IL-33 and its decoy receptor sST2 were measured by immunoassays. We observed a rapid and transient surge of IL-33 in a subset of critically injured patients. These patients had more widespread tissue injuries and a greater degree of early coagulopathy. IL-33 half-life (t We describe for the first time early high-resolution IL-33 concentration kinetics in individual patients after trauma and correlate systemic IL-33 release to clinical data. These findings provide insight into a potentially important axis of danger signaling in humans.
Sections du résumé
BACKGROUND
Alarmins are considered proximal mediators of the immune response after tissue injury. Understanding their biology could pave the way for development of new therapeutic targets and biomarkers in human disease, including multiple trauma. In this study we explored high-resolution concentration kinetics of the alarmin interleukin-33 (IL-33) early after human trauma.
METHODS
Plasma samples were serially collected from 136 trauma patients immediately after hospital admission, 2, 4, 6, and 8 h thereafter, and every morning in the ICU. Levels of IL-33 and its decoy receptor sST2 were measured by immunoassays.
RESULTS
We observed a rapid and transient surge of IL-33 in a subset of critically injured patients. These patients had more widespread tissue injuries and a greater degree of early coagulopathy. IL-33 half-life (t
CONCLUSIONS
We describe for the first time early high-resolution IL-33 concentration kinetics in individual patients after trauma and correlate systemic IL-33 release to clinical data. These findings provide insight into a potentially important axis of danger signaling in humans.
Identifiants
pubmed: 33771098
doi: 10.1186/s10020-021-00288-1
pii: 10.1186/s10020-021-00288-1
pmc: PMC8004436
doi:
Substances chimiques
Biomarkers
0
IL1RL1 protein, human
0
IL33 protein, human
0
Interleukin-1 Receptor-Like 1 Protein
0
Interleukin-33
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
29Références
J Trauma Acute Care Surg. 2015 Aug;79(2):301-9
pubmed: 26218701
Nat Immunol. 2016 Feb;17(2):122-31
pubmed: 26784265
J Immunol. 2011 Apr 1;186(7):4375-87
pubmed: 21357533
Lancet. 1991 Dec 7;338(8780):1423-4
pubmed: 1683422
Shock. 2018 Apr;49(4):420-428
pubmed: 28945676
J Immunol. 2012 Apr 1;188(7):3488-95
pubmed: 22371395
Crit Care Med. 2019 Aug;47(8):e614-e622
pubmed: 31162203
Cardiovasc Res. 2010 Sep 1;87(4):769-77
pubmed: 20363761
Clin Exp Allergy. 2016 Jun;46(6):884-7
pubmed: 26850082
Immunity. 2015 Jun 16;42(6):1005-19
pubmed: 26084021
Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):282-7
pubmed: 17185418
J Trauma. 2004 Jun;56(6):1312-20
pubmed: 15211142
World J Emerg Surg. 2019 Jul 19;14:36
pubmed: 31360218
J Invest Dermatol. 2015 Jul;135(7):1771-1780
pubmed: 25739051
Clin Chim Acta. 2018 Dec;487:145-152
pubmed: 30266513
J Trauma. 2003 Jun;54(6):1127-30
pubmed: 12813333
J Leukoc Biol. 2007 Jan;81(1):1-5
pubmed: 17032697
PLoS Med. 2017 Jul 25;14(7):e1002365
pubmed: 28742815
J Transl Med. 2011 Jun 15;9:92
pubmed: 21676213
Am J Physiol Regul Integr Comp Physiol. 2007 Oct;293(4):R1538-44
pubmed: 17652366
Intensive Care Med. 2004 Jul;30(7):1468-73
pubmed: 14991091
J Clin Invest. 2007 Jun;117(6):1538-49
pubmed: 17492053
Trends Immunol. 2009 May;30(5):227-33
pubmed: 19359217
Science. 2002 Apr 12;296(5566):301-5
pubmed: 11951032
J Hepatol. 2017 Sep 21;:
pubmed: 28943296
Ann Rheum Dis. 2016 Mar;75(3):633-5
pubmed: 26659716
PLoS One. 2008 Oct 06;3(10):e3331
pubmed: 18836528
Mediators Inflamm. 2012;2012:315941
pubmed: 22778496
J Leukoc Biol. 2012 Sep;92(3):539-51
pubmed: 22654121
J Intern Med. 2004 Mar;255(3):332-43
pubmed: 14871457
Am J Pathol. 2008 Oct;173(4):1229-42
pubmed: 18787100
J Biol Chem. 2012 Feb 24;287(9):6941-8
pubmed: 22215666
Am J Cardiol. 2015 Apr 2;115(7 Suppl):3B-7B
pubmed: 25665766